Pharmaceutical Supply Chain Security Act

This bill requires the FDA to report on pharmaceutical products and active ingredients imported from China that make up over 20% of U.S. supply, with the report kept confidential. It directs the President to create a national strategy to reduce reliance on China for drugs and key ingredients, including funding projects that diversify manufacturing through international partnerships. The U.S. Development Finance Corporation must prioritize funding for such projects, but only if recipients certify that no more than 25% of key ingredients come from nonmarket economy countries and the project isn't controlled by entities from those countries. This directly affects drug manufacturers seeking federal support and aims to secure U.S. access to critical medicines.